A Multi-center, Prospective Study to Acess Long-term Benefit in HBeAg Positive Chronic Hepatitis B Patients Who Previously Received Standard Peginterferon Alfa Therapy
Latest Information Update: 05 Nov 2021
Price :
$35 *
At a glance
- Drugs Peginterferon alfa-2b (Primary) ; Peginterferon alfa-2a
- Indications Hepatitis B
- Focus Therapeutic Use
- Sponsors Xiamen Amoytop Biotech
- 11 Apr 2021 Status changed from recruiting to completed.
- 29 Jun 2020 Planned End Date changed from 30 Apr 2020 to 31 Dec 2020.
- 29 Jun 2020 Planned primary completion date changed from 30 Apr 2020 to 31 Dec 2020.